Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Varun Beverages drops 3.8% as alcobev pivot, Tunisia JV fail to lift sentiment

1 week ago 2

PROTECT YOURSELF with Orgo-Life® QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

Traded volume surged to 311.13 lakh shares with a turnover of ₹1,333.90 crore, suggesting heavy institutional activity.

Traded volume surged to 311.13 lakh shares with a turnover of ₹1,333.90 crore, suggesting heavy institutional activity.

Shares of Varun Beverages closed sharply lower on Wednesday, falling ₹16.75 or 3.82 per cent to ₹421.25, even as the PepsiCo bottler announced a sweeping strategic expansion into alcoholic beverages and a new overseas joint venture. Traded volume surged to 311.13 lakh shares with a turnover of ₹1,333.90 crore, suggesting heavy institutional activity. The stock opened at ₹447.90, hit a high of the same level, before sliding to a low of ₹420.20, nearly touching its lower band.

The board approved incorporation of KIVA Spirits and Company Limited, a wholly-owned Indian subsidiary, to pursue the Ready-to-Drink (RTD) and alcoholic beverages segment. Prathmesh Mishra, formerly Managing Director for Korea and Japan at Diageo, was appointed CEO and MD of the new entity. The board also cleared a joint venture in Tunisia, Varun Beverages Tunisia SA, to produce carbonated soft drinks, juices, water and dairy, with VBL holding 75 per cent and local partner Bevanda holding the remaining 25 per cent.

Analysts were broadly constructive but cautious. JPMorgan (Overweight, TP ₹530) flagged that investors will seek clarity on manufacturing versus distribution strategy, potential M&A, capex needs and target segments. CLSA (High Conviction Outperform, TP ₹629) was more bullish, noting India’s alcobev market is estimated at roughly $50.8 billion with strong premiumisation tailwinds. Morgan Stanley (Overweight, TP ₹557) noted the move aligns with management’s October 2025 commentary on RTD opportunity.

Despite analyst optimism, the stock’s near-term performance remains under pressure. VBL is down 14.34 per cent year-to-date and 17.17 per cent over the past year, underperforming the Nifty Next 50 significantly. Its 52-week high stands at ₹555.80. Both subsidiaries remain subject to regulatory approvals before operations commence.

Published on August 26, 2026

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway